New dosing strategy aims to fight lung Cancer's spread to the brain
NCT ID NCT07348965
Summary
This study is testing if taking a higher dose of the lung cancer drug furmonertinib every other day is more effective and safe for patients whose cancer has spread to the lining of the brain and spinal cord. It will enroll 42 adults with a specific genetic mutation (EGFR) whose cancer worsened after initial treatment. The main goal is to see if this new dosing schedule can better control the cancer in the nervous system and if it gets more drug into the spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.